Literature DB >> 15951562

Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases.

Miguel Valiente1, Amparo Andrés-Pons, Beatriz Gomar, Josema Torres, Anabel Gil, Caroline Tapparel, Stylianos E Antonarakis, Rafael Pulido.   

Abstract

The tumor suppressor phosphatase PTEN is a key regulator of cell growth and apoptosis that interacts with PDZ domains from regulatory proteins, including MAGI-1/2/3, hDlg, and MAST205. Here we identified novel PTEN-binding PDZ domains within the MAST205-related proteins, syntrophin-associated serine/threonine kinase and MAST3, characterized the regions of PTEN involved in its interaction with distinctive PDZ domains, and analyzed the functional consequences on PTEN of PDZ domain binding. Using a panel of PTEN mutations, as well as PTEN chimeras containing distinct domains of the related protein TPTE, we found that the PTP and C2 domains of PTEN do not affect PDZ domain binding and that the C-terminal tail of PTEN (residues 350-403) provides selectivity to recognize specific PDZ domains from MAGI-2, hDlg, and MAST205. Binding of PTEN to the PDZ-2 domain from MAGI-2 increased PTEN protein stability. Furthermore, binding of PTEN to the PDZ domains from microtubule-associated serine/threonine kinases facilitated PTEN phosphorylation at its C terminus by these kinases. Our results suggest an important role for the C-terminal region of PTEN in the selective association with scaffolding and/or regulatory molecules and provide evidence that PDZ domain binding stabilizes PTEN and targets this tumor suppressor for phosphorylation by microtubule-associated serine/threonine kinases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951562     DOI: 10.1074/jbc.M504761200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  PDZ domain-containing 1 (PDZK1) protein regulates phospholipase C-β3 (PLC-β3)-specific activation of somatostatin by forming a ternary complex with PLC-β3 and somatostatin receptors.

Authors:  Jung Kuk Kim; Ohman Kwon; Jinho Kim; Eung-Kyun Kim; Hye Kyung Park; Ji Eun Lee; Kyung Lock Kim; Jung Woong Choi; Seyoung Lim; Heon Seok; Whaseon Lee-Kwon; Jang Hyun Choi; Byoung Heon Kang; Sanguk Kim; Sung Ho Ryu; Pann-Ghill Suh
Journal:  J Biol Chem       Date:  2012-04-23       Impact factor: 5.157

3.  PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression.

Authors:  Sandra Jurado; Marion Benoist; Argentina Lario; Shira Knafo; Cortney N Petrok; José A Esteban
Journal:  EMBO J       Date:  2010-07-13       Impact factor: 11.598

4.  Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function.

Authors:  Alexandra Zanin-Zhorov; Jiqiang Lin; Jose Scher; Sudha Kumari; David Blair; Keli L Hippen; Bruce R Blazar; Steven B Abramson; Juan J Lafaille; Michael L Dustin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

5.  Hypomethylation within gene promoter regions and type 1 diabetes in discordant monozygotic twins.

Authors:  Emon Elboudwarej; Michael Cole; Farren B S Briggs; Alexandra Fouts; Pamela R Fain; Hong Quach; Diana Quach; Elizabeth Sinclair; Lindsey A Criswell; Julie A Lane; Andrea K Steck; Lisa F Barcellos; Janelle A Noble
Journal:  J Autoimmun       Date:  2016-01-09       Impact factor: 7.094

6.  PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Authors:  Shira Knafo; Cristina Sánchez-Puelles; Ernest Palomer; Igotz Delgado; Jonathan E Draffin; Janire Mingo; Tina Wahle; Kanwardeep Kaleka; Liping Mou; Inmaculada Pereda-Perez; Edvin Klosi; Erik B Faber; Heidi M Chapman; Laura Lozano-Montes; Ana Ortega-Molina; Lara Ordóñez-Gutiérrez; Francisco Wandosell; Jose Viña; Carlos G Dotti; Randy A Hall; Rafael Pulido; Nashaat Z Gerges; Andrew M Chan; Mark R Spaller; Manuel Serrano; César Venero; José A Esteban
Journal:  Nat Neurosci       Date:  2016-01-18       Impact factor: 24.884

7.  Association of PTEN gene polymorphisms with liver cancer risk.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation.

Authors:  Fumiaki Okahara; Kouichi Itoh; Akira Nakagawara; Makoto Murakami; Yasunori Kanaho; Tomohiko Maehama
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

9.  MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Dan Li; Ruiting Lin; Gina N Alesi; Xu Wang; Hee-Bum Kang; Lina Song; Dongsheng Wang; Guojing Zhang; Jun Fan; Titus J Boggon; Lu Zhou; Jeanne Kowalski; Cheng-Kui Qu; Conor E Steuer; Georgia Z Chen; Nabil F Saba; Lawrence H Boise; Taofeek K Owonikoko; Fadlo R Khuri; Kelly R Magliocca; Dong M Shin; Sagar Lonial; Sumin Kang
Journal:  Cancer Cell       Date:  2018-07-19       Impact factor: 31.743

10.  Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL.

Authors:  Gabriel J Sandoval; Daniel B Graham; Grzegorz B Gmyrek; Holly M Akilesh; Keiko Fujikawa; Benedicte Sammut; Deepta Bhattacharya; Shuba Srivatsan; Alfred Kim; Andrey S Shaw; Katherine Yang-Iott; Craig H Bassing; Eric Duncavage; Ramnik J Xavier; Wojciech Swat
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.